Skip to main content
. 2021 May 25;12(6):536. doi: 10.1038/s41419-021-03834-1

Fig. 8. Circ_0001367 inhibited the glioma malignancy phenotype by targeting the miR-431/NRXN3 axis.

Fig. 8

A, B qRT-PCR and western blot analysis of NRXN3 expression in LN229 and T98G cell lines transfected with sh-circ_0001367, miR-431 inhibitors or sh-circ_0001367 + miR-431 inhibitors. C, D Clone formation assay to evaluate the proliferation of LN229 and T98G cells transfected with sh-circ_0001367, miR-431 inhibitors or sh-circ_0001367 + miR-431 inhibitors. E–H EdU assay to measure the proliferation of LN229 and T98G cells transfected with sh-circ_0001367, miR-431 inhibitors or sh-circ_0001367 + miR-431 inhibitors. I, J Transwell assay to detect the migration of LN229 and T98G cells transfected with sh-circ_0001367, miR-431 inhibitors or sh-circ_0001367 + miR-431 inhibitors. K, L Transwell assay to analyse the invasion of LN229 and T98G cells transfected with sh-circ_0001367, miR-431 inhibitors or sh-circ_0001367 + miR-431 inhibitors. Each experiment was performed in triplicate. Data are expressed as mean ± SD, **P < 0.01.